Company profile: BriaCell Therapeutics
1.1 - Company Overview
Company description
- Provider of immuno-oncology therapeutics developing targeted approaches for cancer management, including Bria-IMT™, a cell-based immunotherapy for advanced metastatic breast cancer that stimulates the immune system to target and kill cancer cells, and Bria-OTS™, a personalized off-the-shelf immunotherapy for advanced breast cancer engineered to match patients' HLA types.
Products and services
- Bria-OTS™: A personalized off-the-shelf immunotherapy for advanced breast cancer, HLA-matched to patients for targeted treatment, engineered to align immune recognition with individual HLA profiles
- Bria-IMT™: A cell-based immunotherapy for advanced metastatic breast cancer that stimulates the immune system to target and kill cancer cells
- Targeted Cancer Management Approaches: The company develops targeted and effective approaches for the management of cancer in immuno-oncology, biotechnology-based
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BriaCell Therapeutics
Caelum Biosciences
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology developing treatments for rare and life-threatening diseases, with lead asset CAEL-101 (mAb 11-1F4), a novel antibody licensed from Columbia University in January 2017 for the treatment of amyloid light chain (AL) amyloidosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Caelum Biosciences company profile →
Elusys Therapeutics
HQ: United States
Website
- Description: Provider of antibody therapeutics for infectious disease, including ANTHIM (obiltoxaximab), a monoclonal anthrax antitoxin used to mitigate the effects of anthrax exposure, licensed in the United States and Canada, and NYXTHRACIS (obiltoxaximab), the same antitoxin licensed in Great Britain and the European Union.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elusys Therapeutics company profile →
CiMaas
HQ: The Netherlands
Website
- Description: Provider of immunotherapies engaging the immune system to treat cancers not cured by current standard of care, including CIM201 adoptive NK cell therapy using proprietary NK expansion for high cytotoxicity; CIM101 F012 feeder cells to rapidly expand NK cells under licensing; and CIM401 adoptive CAR-NK therapy targeting solid tumors, initially breast cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CiMaas company profile →
iTeos Therapeutics
HQ: United States
Website
- Description: Provider of immuno-oncology drug discovery and development focused on tumor immunology and the metabolism of the tumor microenvironment, delivering small molecule immunomodulators and antibody therapies for cancer. Portfolio includes EOS-448 (anti-TIGIT IgG1), Inupadenant (A2AR inhibitor), and EOS-984 (preclinical). Conducts clinical trials and advances monotherapy and combination therapy approaches across cancer indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iTeos Therapeutics company profile →
Mologen
HQ: Germany
Website
- Description: Provider of biopharmaceutical research and clinical development of innovative drugs for cancer and infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mologen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BriaCell Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BriaCell Therapeutics
2.2 - Growth funds investing in similar companies to BriaCell Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BriaCell Therapeutics
4.2 - Public trading comparable groups for BriaCell Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →